rs2277844

GWAS Catalog Trait Associations (5)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement

Karjalainen MK et al. Genome-wide characterization of circulating metabolic biomarkers. Nature 628(8006):130-138 (2024)
Allele A
OR 0.03
p 1.0e-12
N 136,016
Large GWAS
multi-ancestry

lymphocyte count

Allele A
OR 0.01
p 3.0e-10
N 524,923
Large GWAS
European

triglyceride measurement, blood VLDL cholesterol amount

Karjalainen MK et al. Genome-wide characterization of circulating metabolic biomarkers. Nature 628(8006):130-138 (2024)
Allele A
OR 0.02
p 1.0e-9
N 136,016
Large GWAS
multi-ancestry

body mass index

Koskeridis F et al. Pleiotropic genetic architecture and novel loci for C-reactive protein levels. Nature Communications 13(1):6939 (2022)
Allele A
OR 0.01
p 7.0e-9
N 694,649
Large GWAS
European

Research that mentions this SNP (1)

Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis
AssociationN=8,075Chang YC et al.(2012)· Journal of Molecular Medicine

This case-control association study identified rs10483032 in the CBR3 gene as associated with type 2 diabetes and insulin resistance in Chinese populations (combined OR = 1.29, 95% CI = 1.14-1.47, P < 0.0001). The association was replicated in multiple Chinese samples and validated in the FUSION GWAS. Functional studies demonstrated CBR3 expression increases during adipocyte differentiation, and CBR3 knockdown enhanced adipogenesis, suggesting the risk variant modulates type 2 diabetes susceptibility through effects on adipogenesis and insulin sensitivity.

Traits studied:Fasting glucoseFasting insulinHOMA-IRInsulin resistanceType 2 diabetes

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…